5 CDER directors in one year? Turnover threatens ‘institutional memory’ at US health agencies.

Rapid movement among regulators’ top brass has contributed to an inconsistent strategic direction — but there’s hope in bureaucracy.

By Michael Gibney • Dec. 16, 2025

After years of debate, the Biosecure Act could be headed for Trump’s desk

The revised version of the bill softens compliance burdens between U.S. pharma firms and Chinese suppliers, but still has teeth.

By Kelly Bilodeau • Dec. 15, 2025

Explore the Trendline➔

Oncology R&D

Cancer research remains a prime focus for the industry and often leads to pharma’s most impactful breakthroughs.   

By PharmaVoice staff

Amylyx pins its next hopes on a niche drug in the obesity space

A lot is riding on Amylyx’s late-stage candidate for post-bariatric hypoglycemia.

By Meagan Parrish • Dec. 12, 2025

Pharma’s top deals in 2025

The year’s three largest acquisitions signal where pharma is willing to pay big for promising candidates.

By Michael Gibney • Dec. 11, 2025

Another genetic testing company? Why a different approach could boost drug predictions and R&D.

Genetic tests could soon play a larger role in clinical trials and predicting adverse events.

By Alexandra Pecci • Dec. 10, 2025

Will 2026 be pharma’s M&A breakout year?

Big Pharma needs new products to replenish pipelines and has plenty of money in the coffers, but looming uncertainties could stymie dealmaking again.

By Kelly Bilodeau • Dec. 10, 2025

How Lilly uses Big Pharma heft to lift up-and-coming biotechs

With great power comes great responsibility, and Eli Lilly is employing financial success and technical know-how to give smaller biotechs a leg up.

By Michael Gibney • Dec. 9, 2025

Standout drug approvals in 2025

Despite ongoing turbulence at the FDA, pharma has delivered several notable breakthroughs to the market.

By Kelly Bilodeau • Dec. 8, 2025

2026: The year AI’s role in pharma shifts from analysis to action

2026 will mark AI’s evolution in pharma, turning intelligence into action across the value chain.

By Prashant Parab • Dec. 8, 2025

FDA conflicts of interest extend beyond adcomm experts

Many speakers at public meetings report conflicts while showing support for new drugs, according to recent analysis.

By Meagan Parrish • Dec. 5, 2025

BeOne brought Brukinsa to the blood cancer mountaintop. Can it hit those heights again?

The company’s chief medical officer discusses its trajectory with the blockbuster Brukinsa and its strong hematology pipeline.

By Michael Gibney • Dec. 4, 2025

4 major changes at the FDA this year

The most impactful regulatory shifts for pharma in 2025 and how the industry can take advantage of new policies. 

By Alexandra Pecci • Dec. 3, 2025

Hemophilia gene therapies are struggling on the market, even as innovation soars

The business case for hemophilia gene therapy still isn’t adding up due to persistent market barriers.

By Kelly Bilodeau • Dec. 3, 2025

Novo, J&J Alzheimer’s clinical flops teach bruised field valuable lessons

November was a tough month for highly anticipated Alzheimer’s readouts with a GLP-1 and tau-targeting drug coming up short in late-stage trials.

By Michael Gibney • Dec. 2, 2025

A drugmaker charts a path through pharma’s ethical minefields

As the science behind pharma breakthroughs becomes more complex, bioethicists are helping companies navigate moral quandaries.

By Kelly Bilodeau • Dec. 1, 2025

Along with NIH cuts come risks to patient safety and scientific data

The abrupt withdrawal of research funds affected 74,000 clinical trial participants, including some already taking the drugs being studied.

By Kelly Bilodeau • Nov. 26, 2025

4 takeaways from pharma’s manufacturing boom

As pharma’s U.S. facility investments top $370 billion over the next five years, there are a few things to keep in mind, according to construction experts.

By Alexandra Pecci • Nov. 25, 2025

Eli Lilly becomes first drugmaker to hit $1 trillion in market value

The pharmaceutical company’s success developing medicines for obesity has swelled its worth to levels associated with tech titans like Apple and Google and dwarfed that of its drugmaking peers.

By Ned Pagliarulo , Jonathan Gardner • Nov. 24, 2025

What’s next in the eye disease pipeline?

An early gene therapy breakthrough spurred investments, but can the industry maintain momentum?  

By Kelly Bilodeau • Nov. 24, 2025

Pharma faces a critical ‘turning point’ in 2026, years in the making

While Trump’s manufacturing and pricing deals with pharma shape the industry’s future, COVID’s impact still ripples throughout the health landscape.

By Michael Gibney • Nov. 21, 2025

How do Big Pharma employees rate their CEOs?

There are many ways to steer the ship as the top exec of a large pharma company. Here are the ones employees approve of the most — as well as those who could polish their image a little more.

By Alexandra Pecci • Nov. 20, 2025

As Madrigal faces MASH rivals, keeping patients is as critical as finding new ones

Madrigal’s drug Rezdiffra has exceeded expectations, and the company plans to stay ahead of incoming competition with a highly targeted patient approach.

By Kelly Bilodeau • Nov. 19, 2025

Amylin could reign supreme in the next wave of obesity drugs

With investment in amylin analogs on the rise for weight management, three key candidates are inching closer to critical readouts.

By Alivia Kaylor • Nov. 18, 2025

The next leap in Alzheimer’s R&D is coming, but not around the corner

While a couple drugs have reached the market, their effects are still modest, and experts say a true paradigm shift is still a ways off.

By Alexandra Pecci • Nov. 17, 2025

Is that pharma influencer human or AI?

Agentic AI is making its way into pharma marketing — and raising a slew of potential challenges around regulations and ethics.

By Meagan Parrish • Nov. 14, 2025